Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Master Protocol for ALS Interventions
NCT07571200Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of LY4256984 in amyotrophic lateral sclerosis (ALS), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants Allocated to Each of the Intervention-Specific Appendices (ISA) at 96 weeks. Started May 2026; status: recruiting.
02
Drugs
LY4256984
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07571200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07571200.